Akèy › Leksemi mieloïd egi › Tennessee › Nashville
Etid klinik pou Leksemi mieloïd egi nan Nashville, TN
21 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Ap rekriteFaz 1
- Tristar Centennial Medical Center /ID# 275831, Nashville
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Vanderbilt Ingram Cancer Center, Nashville
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Ap rekriteFaz 1
- Sarah Cannon Center for Blood Cancer at TriStar Centennia, Nashville
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Ap rekriteFaz 3
- The Children's Hospital at TriStar Centennial, Nashville
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Ap rekriteFaz 1
- Sarah Cannon Research Insitute, Nashville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Vanderbilt University Medical Center, Nashville
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Ap rekriteFaz 1
- Vanderbilt University/Ingram Cancer Center, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Vanderbilt University, Ingram Cancer Center, Nashville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Vanderbilt University, Nashville
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- Vanderbilt University Medical Center, Nashville
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- TriStar Centennial Medical Center, Nashville
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Ap rekriteFaz 1
- Sarah Cannon Cancer Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- TriStar Bone Marrow Transplant, Nashville
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Ap rekriteFaz 1
- Vanderbilt University, Nashville
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
HPC Offered for PRESERVE Expansion
Ap rekriteEtid obsèvasyon
- Tristar Centennial Medical Center, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Ap rekriteFaz 1
- TriStar Bone Marrow Transplant, Nashville
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.